Trials / Completed
CompletedNCT00766324
PHA-739358 for Treatment of Hormone Refractory Prostate Cancer
A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PHA-739358 | 6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle |
| DRUG | PHA-739358 | 24-hr IV infusion every 2 weeks in a 4-week cycle |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2011-03-01
- Completion
- 2011-04-01
- First posted
- 2008-10-03
- Last updated
- 2014-05-28
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00766324. Inclusion in this directory is not an endorsement.